Accentia Biopharmaceuticals (ABPI) Reports Q3 Loss of $0.25
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) reports a Q3 loss of $0.25, which includes $0.08 attributable to Biovest, which does not compare to the analyst estimate of $0.03.
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology.
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Semtech Corp (SMTC) Misses Q1 EPS by 4c; Guides Q2
- Toro Co. (TTC) Tops Q1 EPS by 13c; Guides FY12 EPS Above Views; to Split Stock
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
